EP0684829A1 - Die rolle der atp-ubiquitin-abhängigen proteolyse in der mhc-1 abhängigen antigenpräsentation und entsprechende inhibitoren - Google Patents

Die rolle der atp-ubiquitin-abhängigen proteolyse in der mhc-1 abhängigen antigenpräsentation und entsprechende inhibitoren

Info

Publication number
EP0684829A1
EP0684829A1 EP94908690A EP94908690A EP0684829A1 EP 0684829 A1 EP0684829 A1 EP 0684829A1 EP 94908690 A EP94908690 A EP 94908690A EP 94908690 A EP94908690 A EP 94908690A EP 0684829 A1 EP0684829 A1 EP 0684829A1
Authority
EP
European Patent Office
Prior art keywords
ubiquitin
inhibitor
cleavage
mhc
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94908690A
Other languages
English (en)
French (fr)
Other versions
EP0684829A4 (de
Inventor
Alfred L. Goldberg
Kenneth L. Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Dana Farber Cancer Institute Inc
Original Assignee
Harvard College
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Dana Farber Cancer Institute Inc filed Critical Harvard College
Publication of EP0684829A1 publication Critical patent/EP0684829A1/de
Publication of EP0684829A4 publication Critical patent/EP0684829A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP94908690A 1993-02-10 1994-01-27 Die rolle der atp-ubiquitin-abhängigen proteolyse in der mhc-1 abhängigen antigenpräsentation und entsprechende inhibitoren. Withdrawn EP0684829A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1606693A 1993-02-10 1993-02-10
US16066 1993-02-10
PCT/US1994/001183 WO1994017816A1 (en) 1993-02-10 1994-01-27 Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof

Publications (2)

Publication Number Publication Date
EP0684829A1 true EP0684829A1 (de) 1995-12-06
EP0684829A4 EP0684829A4 (de) 1997-05-21

Family

ID=21775196

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94908690A Withdrawn EP0684829A4 (de) 1993-02-10 1994-01-27 Die rolle der atp-ubiquitin-abhängigen proteolyse in der mhc-1 abhängigen antigenpräsentation und entsprechende inhibitoren.

Country Status (5)

Country Link
EP (1) EP0684829A4 (de)
JP (1) JPH08507754A (de)
AU (1) AU676721B2 (de)
CA (1) CA2155554A1 (de)
WO (1) WO1994017816A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US5968747A (en) * 1997-12-12 1999-10-19 Incyte Pharmaceuticals, Inc. Ubiquitin-like conjugating protein
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
KR20010080267A (ko) 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
JP2002105080A (ja) * 2000-09-29 2002-04-10 Microbial Chem Res Found 生理活性物質パネポフェナンスリンとその製造法
US20050049294A1 (en) 2003-06-20 2005-03-03 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020804A1 (en) * 1991-05-13 1992-11-26 President And Fellows Of Harvard College Atp-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390629A (en) * 1981-03-30 1983-06-28 President And Fellows Of Harvard College Polypeptide degrading enzymes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020804A1 (en) * 1991-05-13 1992-11-26 President And Fellows Of Harvard College Atp-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JOINT MEETING OF THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE CLINICAL IMMUNOLOGY SOCIETY, DENVER, COLORADO, USA, MAY 21-25, 1993. J IMMUNOL 150 (8 PART 2). 1993. 91A, XP002027836 MICHALEK M T ET AL: "A ROLE OF THE UBIQUITIN -DEPENDENT PROTEOLYTIC PATHWAY IN MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION." *
NATURE (LOND) 363 (6429). 1993. 552-554, XP002027835 MICHALEK M T ET AL: "A ROLE FOR THE UBIQUITIN -DEPENDENT PROTEOLYTIC PATHWAY IN MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION." *
NATURE, vol. 357, no. 6377, 4 June 1992, pages 375-379, XP002027833 GOLDBERG A.L. ET AL.: "Proteolysis, proteasomes and antigen presentation" *
PROC NATL ACAD SCI U S A 89 (11). 1992. 4986-4990, XP002027834 DRISCOLL J ET AL: "AN ATP-STABILIZED INHIBITOR OF THE PROTEASOME IS A COMPONENT OF THE 1500-KDA UBIQUITIN CONJUGATE-DEGRADING COMPLEX." *
See also references of WO9417816A1 *

Also Published As

Publication number Publication date
EP0684829A4 (de) 1997-05-21
AU6169194A (en) 1994-08-29
JPH08507754A (ja) 1996-08-20
CA2155554A1 (en) 1994-08-18
AU676721B2 (en) 1997-03-20
WO1994017816A1 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
Tan et al. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families
US5759994A (en) Recombinant thrombin receptor and related pharmaceuticals
AU676721B2 (en) Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
EP0591316A1 (de) Atp-abhängige protease und verwendung deren inhibitoren in der benahndlung von kachexie und muskelschwund
CA2219964A1 (en) Polypeptide capable of binding interleukin-18 and uses therof
AU721194B2 (en) Thrombin receptor homolog
US6451759B1 (en) Noncleavable Fas ligand
WO1998002579A1 (en) Regulation of apoptosis and in vitro model for studies thereof
WO1998002579A9 (en) Regulation of apoptosis and in vitro model for studies thereof
US20080085853A1 (en) Nuclear targeting by means of bacterial proteins
AU732547B2 (en) Novel cyclin-selective ubiquitin carrier polypeptides
US6558900B2 (en) Regulation of apoptosis and in vitro model for studies thereof
WO1993009808A1 (en) METHODS FOR DETECTING AND ISOLATING uPA-R AND INHIBITING THE BINDING OF uPA TO uPA-R
US6180379B1 (en) Cyclin-selective ubiquitin carrier polypeptides
US6833355B1 (en) Use of protein H as cytostatic agent
AU727222B2 (en) Regulation of apoptosis and in vitro model for studies thereof
WO2000023590A2 (en) INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
MXPA98008070A (en) Novedous polypeptides carriers of selected cybinetines of cicl

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990512